Watch: Looking to RNA-Modifying Proteins to Tackle Cancer
Lexington, MA-based Accent Therapeutics has a new idea to fight cancer. The idea is to develop drugs that target what are called RNA-modifying proteins (RMPs). RMPs modify RNA after they are produced by the DNA but before the RNA is translated into proteins. The activities of some RMPs have been linked to the development of…
This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.
Get featured
Want to get featured in MarketScale Healthcare?
Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.
Lexington, MA-based Accent Therapeutics has a new idea to fight cancer. The idea is to develop drugs that target what are called RNA-modifying proteins (RMPs). RMPs modify RNA after they are produced by the DNA but before the RNA is translated into proteins. The activities of some RMPs have been linked to the development of certain cancers.
Accent believes inhibiting these proteins could be a more precise way of attacking cancer. Only two other companies are attempting to do something similar: U.K.-based Storm Therapeutics and NYC-based Gotham Therapeutics. Accent believes this approach is a fertile field for anticancer drug development.
Your experts belong here
Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.
Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.
